206 related articles for article (PubMed ID: 26635035)
1. von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.
Sorvillo N; Hartholt RB; Bloem E; Sedek M; ten Brinke A; van der Zwaan C; van Alphen FP; Meijer AB; Voorberg J
Haematologica; 2016 Mar; 101(3):309-18. PubMed ID: 26635035
[TBL] [Abstract][Full Text] [Related]
2. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.
Gangadharan B; Ing M; Delignat S; Peyron I; Teyssandier M; Kaveri SV; Lacroix-Desmazes S
Haematologica; 2017 Feb; 102(2):271-281. PubMed ID: 27758819
[TBL] [Abstract][Full Text] [Related]
3. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
4. Limited promiscuity of HLA-DRB1 presented peptides derived of blood coagulation factor VIII.
van Haren SD; Wroblewska A; Herczenik E; Kaijen PH; Ruminska A; ten Brinke A; Meijer AB; Voorberg J
PLoS One; 2013; 8(11):e80239. PubMed ID: 24244658
[TBL] [Abstract][Full Text] [Related]
5. Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells.
Sorvillo N; van Haren SD; Kaijen PH; ten Brinke A; Fijnheer R; Meijer AB; Voorberg J
Blood; 2013 Apr; 121(17):3502-10. PubMed ID: 23372163
[TBL] [Abstract][Full Text] [Related]
6. HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII.
van Haren SD; Herczenik E; ten Brinke A; Mertens K; Voorberg J; Meijer AB
Mol Cell Proteomics; 2011 Jun; 10(6):M110.002246. PubMed ID: 21467215
[TBL] [Abstract][Full Text] [Related]
7. Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells.
Peyron I; Hartholt RB; Pedró-Cos L; van Alphen F; Brinke AT; Lardy N; Meijer AB; Voorberg J
Haematologica; 2018 Jan; 103(1):172-178. PubMed ID: 29025906
[TBL] [Abstract][Full Text] [Related]
8. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells.
Pfistershammer K; Stöckl J; Siekmann J; Turecek PL; Schwarz HP; Reipert BM
Thromb Haemost; 2006 Sep; 96(3):309-16. PubMed ID: 16953272
[TBL] [Abstract][Full Text] [Related]
9. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
[TBL] [Abstract][Full Text] [Related]
10. Interaction of factor VIII and von Willebrand factor and the identification of type 2N von Willebrand disease.
Favaloro EJ
Thromb Res; 2011 Jan; 127(1):2-3. PubMed ID: 21084106
[No Abstract] [Full Text] [Related]
11. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
Oldenburg J; Lacroix-Desmazes S; Lillicrap D
Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
[TBL] [Abstract][Full Text] [Related]
12. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.
Dasgupta S; Repessé Y; Bayry J; Navarrete AM; Wootla B; Delignat S; Irinopoulou T; Kamaté C; Saint-Remy JM; Jacquemin M; Lenting PJ; Borel-Derlon A; Kaveri SV; Lacroix-Desmazes S
Blood; 2007 Jan; 109(2):610-2. PubMed ID: 16985172
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
14. Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor.
Shima M; Yoshioka A; Nakai H; Tanaka I; Sawamoto Y; Kamisue S; Terada S; Fukui H
Int J Hematol; 1991 Dec; 54(6):515-22. PubMed ID: 1724391
[TBL] [Abstract][Full Text] [Related]
15. The effect of von Willebrand factor on activation of factor VIII by factor Xa.
Koedam JA; Hamer RJ; Beeser-Visser NH; Bouma BN; Sixma JJ
Eur J Biochem; 1990 Apr; 189(2):229-34. PubMed ID: 2110896
[TBL] [Abstract][Full Text] [Related]
16. The role of platelet von Willebrand factor in the binding of factor VIII to activated platelets.
Suzuki H; Shima M; Kamisue S; Nakai H; Nogami K; Shibata M; Morichika S; Tanaka I; Giddings JC; Yoshioka A
Thromb Res; 1998 Jun; 90(5):207-14. PubMed ID: 9694242
[TBL] [Abstract][Full Text] [Related]
17. Peptide affinity chromatography of human clotting factor VIII. Screening of the vWF-binding domain.
Necina R; Amatschek K; Schallaun E; Schwinn H; Josic D; Jungbauer A
J Chromatogr B Biomed Sci Appl; 1998 Sep; 715(1):191-201. PubMed ID: 9792510
[TBL] [Abstract][Full Text] [Related]
18. A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor.
Foster PA; Fulcher CA; Houghten RA; Zimmerman TS
Thromb Haemost; 1990 Jun; 63(3):403-6. PubMed ID: 2119526
[TBL] [Abstract][Full Text] [Related]
19. [Structure and function of the factor VIII/von Willebrand factor complex].
Müller G
Z Gesamte Inn Med; 1990 Mar; 45(3):65-8. PubMed ID: 2159676
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
